CLAIM AMENDMENTS

This listing of claims will replace all previous listings of claims.

Listing of Claims:

1. **(Currently amended)** A method comprising: determining whether OX-2/CD200 is upregulated in a subject; and administering to those subjects in which CD200 is upregulated a polypeptide that binds to OX 2/CD200 ~~or an OX-2/CD200 receptor~~, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

2. **(Original)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

3. **(Original)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

4. **(Withdrawn)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

5. **(Withdrawn)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

6. **(Cancelled)**

7. **(Withdrawn)** A method of treating a disease state in which OX-2/CD200 is upregulated comprising administering to a subject afflicted with a disease state in which OX-2/CD200 is upregulated a polypeptide that binds to OX-2/CD200 or to an OX 2/CD200 receptor, the

polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

8. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

9. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

10. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

11. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

12. **(Cancelled)**

13. **(Withdrawn)** A method of treating cancer comprising:
determining whether OX-2/CD200 is upregulated in a subject afflicted with cancer; and
administering to those subjects in which CD200 is upregulated a polypeptide that binds to OX 2/CD200 or an OX-2/CD200 receptor, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

14. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

15. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

16. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

17. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

18. **(Cancelled)**

19. **(Withdrawn)** A method of treating CLL comprising:
determining whether OX-2/CD200 is upregulated in a subject afflicted with CLL; and
administering to those subjects in which CD200 is upregulated a polypeptide that binds to OX 2/CD200 or an OX-2/CD200 receptor, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

20. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

21. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

22. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

23. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

24. **(Cancelled)**

25. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 5, 12 and 13.

26. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 21 and 23.

27. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 29, 37 and 38.

28. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 50, 55 and 56.

29. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 69, 74 and 75.

30. **(Previously presented)** A method as in claim 1 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 88, 93 and 94.

31. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 5, 12 and 13.

32. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 21 and 23.

33. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 29, 37 and 38.

34. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR1 region having a sequence selected from the group consisting of SEQ ED NOS: 50, 55 and 56.

35. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 69, 74 and 75.

36. **(Withdrawn)** A method as in claim 7 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 88, 93 and 94.

37. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 5, 12 and 13.

38. **(Withdrawn)** A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 21 and 23.

39. (**Withdrawn**) A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 29, 37 and 38.

40. (**Withdrawn**) A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 50, 55 and 56.

41. (**Withdrawn**) A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 69, 74 and 75.

42. (**Withdrawn**) A method as in claim 13 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 88, 93 and 94.

43. (**Withdrawn**) A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 5, 12 and 13.

44. (**Withdrawn**) A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 21 and 23.

45. (**Withdrawn**) A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a light chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 29, 37 and 38.

46. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR1 region having a sequence selected from the group consisting of SEQ ID NOS: 50, 55 and 56.

47. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR2 region having a sequence selected from the group consisting of SEQ ID NOS: 69, 74 and 75.

48. **(Withdrawn)** A method as in claim 19 wherein the step of administering a polypeptide comprises administering an antibody containing a heavy chain CDR3 region having a sequence selected from the group consisting of SEQ ID NOS: 88, 93 and 94.

49. **(Currently amended)** A method comprising:
administering a polypeptide that binds to OX-2/CD200 ~~or an OX-2/CD200 receptor~~ to a subject in which CD200 is upregulated, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

50. **(Withdrawn)** A method comprising:
administering a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor to a cancer patient in whom CD200 is upregulated, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

51. **(Withdrawn)** A method comprising:
administering a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor to a CLL patient in whom CD200 is upregulated, the polypeptide being administered in an amount effective to inhibit the immune-suppressing effect of OX-2/CD200.

52. **(Previously presented)** A method as in claim 2 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s.

53. **(Withdrawn)** A method as in claim 8 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s.

54. **(Withdrawn)** A method as in claim 14 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s.

55. **(Withdrawn)** A method as in claim 20 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')2s.

56. **(Not Entered)** A method for determining whether a subject is afflicted with cancer, comprising determining whether OX-2/CD200 is upregulated in said subject.

57. **(Not Entered)** The method of claim 56, wherein upregulation of OX-2/CD200 in said subject is determined using an antibody, or antigen binding fragment thereof, that specifically binds to OX-2/CD200.

58. **(Not Entered)** The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, Fv, scFv, Fab' and $F(ab')_2$.

59. **(Not Entered)** The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, is humanized or human.

60. **(Not Entered)** The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 12, a light chain CDR2 having the sequence set forth in SEQ ID NO: 23, a light chain CDR3 having the sequence set forth in SEQ ID NO: 37, a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 55, a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 74, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 93.

61. **(Not Entered)** The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 5; a light chain CDR2 having the sequence set forth in SEQ ID NO: 21; a light chain CDR3 having the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 88.

62. **(Not Entered)** The method of claim 57, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 13; a light chain CDR2 having the sequence set forth in SEQ ID NO: 23; a light chain CDR3 having the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 94.

63. **(Not Entered)** The method of claim 56, wherein the cancer is chronic lymphocytic leukemia (CLL).

64. **(Not Entered)** The method of claim 56, wherein the cancer is melanoma.

65. **(Not Entered)** The method of claim 56, wherein the method further comprises administering to those subjects afflicted with cancer, an antibody, or antigen binding fragment thereof, that specifically binds to OX-2/CD200.

66. **(Not Entered)** The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, Fv, scFv, Fab' and $F(ab')_2$.

67. **(Not Entered)** The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, is humanized or human.

68. **(Not Entered)** The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 12, a light chain CDR2 having the sequence set forth in SEQ ID NO: 23, a light chain CDR3 having the sequence set forth in SEQ ID NO: 37, a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 55, a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 74, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 93.

69. **(Not Entered)** The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 5; a light chain CDR2 having the sequence set forth in SEQ ID NO: 21; a light chain CDR3 having the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 88.

70. **(Not Entered)** The method of claim 65, wherein the antibody, or antigen-binding fragment thereof, comprises a light chain CDR1 having the sequence set forth in SEQ ID NO: 13; a light chain CDR2 having the sequence set forth in SEQ ID NO: 23; a light chain CDR3 having the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 94.